Antigen-Presenting Cells: Macrophages, Dendritic Cells, and B-Cells

MHC class I molecules have sealed binding clefts holding 8-10 amino acid peptides tightly, requiring precise sizing and preventing accidental peptide exchange. MHC class II molecules have open clefts allowing 13-16 amino acid peptides to extend beyond with looser binding. CD4 binds to class II MHC while CD8 binds to class I MHC, providing co-receptor specificity for helper versus cytotoxic T cell responses. Class I presents intracellular antigens for direct cell killing, while class II presents extracellular antigens to recruit immune help. This structural divergence reflects their distinct functional roles in adaptive immunity.

MHC class I presents endogenous antigens (intracellular proteins like viral proteins) through the proteasome-TAP-ER pathway, enabling detection of intracellular pathogens and cancer cells. MHC class II presents exogenous antigens (extracellular proteins phagocytosed) through the lysosomal pathway, enabling detection of extracellular pathogens. Both classes share structural features: membrane proteins with significant extracellular domains containing peptide-binding grooves.

The immune system distinguishes self from nonself through antigen presentation via two distinct pathways: MHC class I presents endogenous antigens (from inside the cell, such as viral components or cancer neoantigens) to CD8 T cells, while MHC class II presents exogenous antigens (from outside the cell, such as extracellular bacteria) to CD4 T helper cells; both pathways involve specific molecular mechanisms where proteins are processed into peptides, loaded onto MHC molecules, and displayed on the cell surface for immune surveillance.

MHC class I and class II molecules present different types of antigens through distinct cellular pathways. Class I molecules display endogenous antigens (viral peptides) on all nucleated cells, while class II molecules present exogenous antigens (from bacteria or pathogens) on professional antigen-presenting cells. Class I processing involves immunoproteasome degradation of cytoplasmic proteins, peptide transport via TAP into the ER, and loading onto MHC class I molecules. Class II processing involves endocytosis/phagocytosis of extracellular antigens, followed by antigen processing in endosomes and loading onto MHC class II molecules. Both pathways result in antigen-MHC complexes displayed on the cell surface for T cell recognition.

There are two main antigen presentation pathways: the endogenous pathway (for intracellular antigens) using MHC class I and CD8+ T cells, and the exogenous pathway (for extracellular antigens) using MHC class II and CD4+ T cells. APCs always present antigens on specific MHC molecules regardless of antigen origin. Exogenous antigens are presented on MHC class II, while endogenous antigens are presented on MHC class I. This restriction ensures appropriate immune responses. MHC class II molecules associate with an invariant chain in the endoplasmic reticulum, which blocks the peptide-binding groove to prevent binding of endogenous peptides. After endosomal acidification, the invariant chain is degraded, and CLIP is removed by HLA-DM, allowing exogenous peptides to bind. The loaded MHC class II-peptide complex is transported to the cell surface. Certain MHC alleles are associated with increased susceptibility to autoimmune diseases, such as HLA-B27 with ankylosing spondylitis. Having specific MHC alleles increases the probability of developing certain autoimmune conditions.

Helper T cells (CD4+ Tfh cells) activate B cells through direct cell-cell contact via CD40L-CD40 interaction and cytokine secretion, enabling B cells to undergo isotype switching and somatic hypermutation; this thymus-dependent activation process requires B cells to first internalize antigen through receptor-mediated endocytosis, process it into peptides, and present them on MHC class II molecules for T cell recognition, ultimately leading to affinity maturation and enhanced antibody production.

During B-cell maturation in the germinal center, somatic hypermutation introduces rapid single base pair changes into the variable regions of antibody genes (affecting both heavy and light chains), thereby increasing antibody affinity for antigens; simultaneously, class switch recombination, mediated by a recombinase enzyme complex, switches the antibody class by cutting and recombining the heavy chain constant region genes (mu/delta/gamma/epsilon/alpha), with the specific isotype (IgM, IgG, IgA, or IgE) determined by cytokines from T follicular helper cells based on pathogen location—interferon gamma promotes IgG for systemic infections, TGF-beta promotes IgA for mucosal defense, and IL-4 promotes IgE for parasitic infections.

Effective B cell activation requires coordinated movement between B cells and T helper cells. After initial activation, B cells express CCR7 and migrate toward the T cell zone while T helper cells express CXCR5 and move toward B cell follicles. At the junction, follicular helper T cells provide CD40L signals and IL-21 cytokine support. Germinal centers form in secondary follicles with dark zones containing rapidly proliferating centroblasts (doubling every 6-12 hours) and light zones where centrocytes undergo antigen selection. Somatic hypermutation introduces random mutations in variable regions at rates 100-1000x normal, affecting CDR regions. In the light zone, high-affinity variants survive while low-affinity cells undergo apoptosis. Class switching involves AID-mediated DNA recombination bringing different constant regions together, with cytokine environment determining which isotype is produced.

B cell activation requires antigen crosslinking of receptors or complement-mediated signaling through CD21. Activated B cells undergo clonal expansion and somatic hypermutation, potentially improving antibody affinity. Without T cell help, B cells produce only IgM antibodies through T-independent responses lacking memory formation. With T cell help, B cells migrate toward paracortical areas, receive CD40-CD40 ligand signals, and undergo class switching via AID-mediated DNA recombination. This enables production of IgG, IgA, or IgE antibodies. Hyper-IgM syndrome demonstrates the clinical consequences of defective class switching, causing severe recurrent infections due to inability to produce protective IgA antibodies.

Somatic hypermutation is the process by which B cells acquire mutations in the variable regions of their immunoglobulin genes. These mutations occur in the germinal centers and can increase or decrease the affinity of BCRs for their specific antigen. B cells with higher-affinity receptors are selected to survive and proliferate, while those with lower-affinity receptors undergo apoptosis. Class switch recombination is the process by which B cells change the class of immunoglobulin they produce (from IgM to IgG, IgA, or IgE). This process occurs in germinal centers and is regulated by cytokines secreted by helper T cells. Different helper T cell subsets secrete different cytokines that direct B cells to switch to specific antibody classes: Th1 cells secrete IFN-gamma (promotes IgG), Th2 cells secrete IL-4 (promotes IgE), and Tfh cells secrete IL-21 (promotes IgG). Different antibody classes have distinct effector functions: IgM activates complement and provides initial immune response; IgG provides long-term immunity and crosses the placenta; IgE mediates allergic reactions and parasitic defense; IgA provides mucosal immunity.

Antigens (food, bacterial, viral, parasitic, dental, environmental) cross the intestinal mucosa due to hyperpermeability. Antigen-presenting cells process these antigens and present peptides via HLA molecules to T-cells. HLA Class II presents to CD4+ T-cells, while HLA Class I presents to CD8+ cytotoxic T-cells. This triggers immune responses that can develop into autoimmune diseases including ankylosing spondylitis, rheumatoid arthritis, multiple sclerosis, Crohn's disease, and diabetes. The disease classification includes systemic autoimmune diseases (lupus, Sjögren's syndrome, polymyositis, scleroderma, rheumatoid arthritis) and organ-specific diseases (thyroid, pancreas, intestine, liver). Disease expression requires both genetic predisposition (HLA) and environmental triggers.

The adaptive immune response involves lymphocytes (T-cells and B-cells) that can develop memory. Dendritic cells or antigen-presenting cells sample their environment through pinocytosis and, when activated, mature into cells with dendrites that activate CD4 helper cells and CD8 cytotoxic T-cells. In cancer patients, these antigen-presenting cells are often dysfunctional—insufficient in number, refractory to stimulation, or presenting antigens in ways that suppress rather than activate T-cells. This dysfunction explains why immunotherapy approaches aim to generate functional antigen-presenting cells outside the immunosuppressive tumor microenvironment.

This section introduces the ASPIRE (Antigen Self-Presenting Immune Reversal Engineered) platform representing an integrated cancer immunotherapy strategy. Traditional multi-antigen vaccines failed in immunosuppressive tumor environments due to PD-L1/PD-1 checkpoint expression. ASPIRE combines antigen self-presentation with immunosuppression reversal by incorporating anti-PD-1 antibodies onto DC nano vesicles. In LLC lung carcinoma models, PV-1 DC nano vesicles achieved tumor regression in 8/10 animals, while B7-1 knockouts showed progression. In MC38 colon cancer models, ASPIRE treatment reduced dysfunctional PD-1+ CD8+ T cells while increasing functional antigen-specific T cells, achieving 100% survival at least two months post-treatment. This dual-function platform demonstrates remarkable therapeutic efficacy by stimulating cytotoxic T lymphocyte responses and enhancing immune checkpoint blockade.

Cancer cells can evade immune detection by failing to properly present antigens. This can occur through: (1) failure to produce the antigenic peptides, (2) failure to express MHC molecules on the cell surface, or (3) production of structurally altered proteins that cannot be recognized by the immune system. Without proper antigen presentation, the dual recognition requirement cannot be satisfied, and the immune system fails to eliminate the cancer cell. This mechanism is particularly important in understanding why some cancer cells evade immune detection while others do not.

Cancer immunotherapy harnesses the immune system to fight cancer, utilizing active immunotherapy where vaccines stimulate patient immune responses. The immune system recognizes tumor cells through antigen presentation: tumor proteins are processed into peptides by proteasomes, transported via TAP proteins to the endoplasmic reticulum, bound to MHC molecules, and displayed on cell surfaces. Cytotoxic T lymphocytes recognize these MHC-peptide complexes and kill tumor cells. Understanding this fundamental mechanism enables rational vaccine design targeting specific tumor antigens.